Patient and transplant characteristics by transplant type
| . | Total cohort (N = 307) . | Autologous HCT (n = 102; 33%) . | Allogeneic HCT (n = 205; 67%) . |
|---|---|---|---|
| Age at HCT, median (range), y | 8.5 (0.1-27.3) | ||
| Sex | |||
| Male | 195 (64) | 73 (72) | 122 (60) |
| Female | 112 (36) | 29 (28) | 83 (40) |
| Race | |||
| White | 182/206 (88.4) | 65/75 (87) | 117/131 (89.3) |
| African American | 13/206 (6.3) | 7/75 (9) | 6/131 (4.6) |
| Asian | 8/206 (3.8) | 3/75 (4) | 5/131 (3.8) |
| Middle Eastern | 2/206 (1) | 0/75 (0) | 2/131 (1.5) |
| Native American/Alaskan Native | 1/206 (0.5) | 0/75 (0) | 1/131 (0.8) |
| No data | 101 | 27 | 74 |
| HCT | |||
| 1 | 266 (87) | 75 (73.5) | 191 (93) |
| 2 | 32 (10) | 20 (19.6) | 12 (6) |
| 3 | 9 (3) | 7 (6.9) | 2 (1) |
| Transplant indication | |||
| Hematologic malignancy | 104 (34) | 18 (17.6) | 86 (42) |
| Immunodeficiency | 67 (22) | 4 (3.9) | 63 (31) |
| Heme (SCD, Thal, aAA, BMF) | 46 (15) | 0 (0) | 46 (22) |
| Solid tumor | 73 (24) | 73 (71.6) | 0 (0) |
| Metabolic/neurodegenerative | 17 (6) | 7 (6.9) | 10 (5) |
| TA-TMA | |||
| Provider diagnosed | 8 (2.6) | 6 (6) | 2 (1) |
| Cho criteria | 62 (20) | 13 (13) | 49 (24) |
| Jodele criteria | 110 (36) | 21 (21) | 89 (43) |
| Time to TA-TMA diagnosis, median (range), d | |||
| Cho criteria | 29 (5-97) | 20 (5-71) | 30 (11-97) |
| Jodele criteria | 30 (1-97) | 19 (3-71) | 31 (1-97) |
| Allogeneic HCT recipients only | |||
| Donor | |||
| Related | 82 (40) | ||
| Unrelated | 123 (60) | ||
| HLA match* | |||
| 10/10 | 140 (74) | ||
| >9/10 | 48 (26) | ||
| Cell source | |||
| Bone marrow | 181 (88.3) | ||
| Peripheral blood | 7 (3.4) | ||
| Umbilical cord | 17 (8.3) | ||
| Conditioning intensity | |||
| Myeloablative | 137 (66.8) | ||
| Reduced intensity | 53 (25.9) | ||
| Nonmyeloablative | 15 (7.3) |
| . | Total cohort (N = 307) . | Autologous HCT (n = 102; 33%) . | Allogeneic HCT (n = 205; 67%) . |
|---|---|---|---|
| Age at HCT, median (range), y | 8.5 (0.1-27.3) | ||
| Sex | |||
| Male | 195 (64) | 73 (72) | 122 (60) |
| Female | 112 (36) | 29 (28) | 83 (40) |
| Race | |||
| White | 182/206 (88.4) | 65/75 (87) | 117/131 (89.3) |
| African American | 13/206 (6.3) | 7/75 (9) | 6/131 (4.6) |
| Asian | 8/206 (3.8) | 3/75 (4) | 5/131 (3.8) |
| Middle Eastern | 2/206 (1) | 0/75 (0) | 2/131 (1.5) |
| Native American/Alaskan Native | 1/206 (0.5) | 0/75 (0) | 1/131 (0.8) |
| No data | 101 | 27 | 74 |
| HCT | |||
| 1 | 266 (87) | 75 (73.5) | 191 (93) |
| 2 | 32 (10) | 20 (19.6) | 12 (6) |
| 3 | 9 (3) | 7 (6.9) | 2 (1) |
| Transplant indication | |||
| Hematologic malignancy | 104 (34) | 18 (17.6) | 86 (42) |
| Immunodeficiency | 67 (22) | 4 (3.9) | 63 (31) |
| Heme (SCD, Thal, aAA, BMF) | 46 (15) | 0 (0) | 46 (22) |
| Solid tumor | 73 (24) | 73 (71.6) | 0 (0) |
| Metabolic/neurodegenerative | 17 (6) | 7 (6.9) | 10 (5) |
| TA-TMA | |||
| Provider diagnosed | 8 (2.6) | 6 (6) | 2 (1) |
| Cho criteria | 62 (20) | 13 (13) | 49 (24) |
| Jodele criteria | 110 (36) | 21 (21) | 89 (43) |
| Time to TA-TMA diagnosis, median (range), d | |||
| Cho criteria | 29 (5-97) | 20 (5-71) | 30 (11-97) |
| Jodele criteria | 30 (1-97) | 19 (3-71) | 31 (1-97) |
| Allogeneic HCT recipients only | |||
| Donor | |||
| Related | 82 (40) | ||
| Unrelated | 123 (60) | ||
| HLA match* | |||
| 10/10 | 140 (74) | ||
| >9/10 | 48 (26) | ||
| Cell source | |||
| Bone marrow | 181 (88.3) | ||
| Peripheral blood | 7 (3.4) | ||
| Umbilical cord | 17 (8.3) | ||
| Conditioning intensity | |||
| Myeloablative | 137 (66.8) | ||
| Reduced intensity | 53 (25.9) | ||
| Nonmyeloablative | 15 (7.3) |
Unless otherwise noted, data are n (%) or n/N (%).
aAA, aquired aplastic anemia; BMF, bone marrow failure; Heme, benign hematology (including sickle cell disease, beta-thalassemia, aquired aplastic anemia, and inherited bone marrow failure syndromes); SCD sickle cell disease; Thal, beta thalassemia.
Bone marrow transplant and peripheral blood stem cell source only.